Recruiting
Phase 2

PET Adapted Brentuximab Vedotin and Pembrolizumab in Combination With Doxorubicin and Dacarbazine in Classic Hodgkin Lymphoma

Sponsor:

M.D. Anderson Cancer Center

Code:

NCT05922904

Conditions

Hodgkin Lymphoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Brentuximab vedotin

Doxorubicin Hydrochloride

Pembrolizumab

Dacarbazine

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information